ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Japan's Shionogi primed to mass-produce coronavirus vaccine in 2021

Drugmaker rolls dice with bulking up capacity before clinical trials launch

Drugmakers are racing to develop a vaccine for the novel coronavirus, seen here in orange in a scanning electron microscope image.   © U.S. National Institute of Allergy and Infectious Diseases, NIH

TOKYO -- As Shionogi & Co. races to bring a possible coronavirus vaccine to the market next year, the Japanese drug manufacturer is considering plans to expand production capabilities before clinical trials start.

"While keeping pace with rivals, I expect a release date by around fall 2021 at the latest," Shionogi President and CEO Isao Teshirogi told Nikkei in an interview.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more